Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

Is It Too Late To Consider Ford (F) After Its 51% One Year Surge?

View original at finance.yahoo.com
Is It Too Late To Consider Ford (F) After Its 51% One Year Surge? Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Over 7 million investors trust Simply Wall St to stay informed about their stock portfolios

    60% confidence
  • Ford Motor stock returned 11.4% over the past week, 18.2% over the past month, 11.9% year-to-date, and 51.2% over the past year

    60% confidence
  • Ford Motor's 3-year return is 49.1% and 5-year return is 38.6%

    60% confidence
  • The P/S ratio is a useful valuation metric for companies generating meaningful revenue, especially when earnings are volatile or distorted by one-off items

    60% confidence
  • Projected free cash flow for Ford Motor in 2028 is $7.74 billion, with additional estimates extending through 2035

    60% confidence
  • Ford Motor is undervalued by 13.8% based on DCF analysis, with an estimated intrinsic value of $17.33 per share versus a market price of approximately $14.93

    60% confidence
  • There are 49 additional high quality undervalued stocks identified beyond Ford Motor

    60% confidence
  • Ford Motor currently scores 4 out of 6 on Simply Wall St's valuation checks

    60% confidence
  • Ford Motor is currently generating trailing twelve month free cash flow of approximately $9.83 billion

    60% confidence

Data points we hold from this source

Ford Motor Company · cash7.74 USD
Ford Motor Company · stock price14.93 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com